Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2018-07
-
The synthetic route to M developed by Rice was utilized
2023-06-14

The synthetic route to M100907 developed by Rice was utilized, however, the chiral resolution was carried out at an earlier stage to provide the possibility of introducing different substituents onto the piperidinyl group. The conditions for this resolution were different from previously reported.
-
PF also a dual Aurora A and
2023-06-13

PF-03814735, also a dual Aurora-A and Aurora-B inhibitor, was administered in a phase I dose escalation study in a 3-weekly pitavastatin for 5 or 10 consecutive days [69], [70]. To date 25 patients have been included in 7 dose levels (5–100mg/day for 5 days). Using the 5-day schedule the MTD was de
-
In vascular endothelial cells L arginine
2023-06-12

In vascular endothelial cells, L-arginine produces nitric oxide (NO) under the action of nitric oxide synthase (NOS), and nitric oxide can activate guanylate cyclase to produce a large amount of cGMP, thereby relaxing vascular smooth muscle and expanding blood vessels. Numerous studies have confirme
-
Herein we employ an adapted targeted quantitative proteomic
2023-06-02

Herein we employ an adapted targeted quantitative proteomic isotope dilution method, developed in our laboratory [[18], [19], [20], [21]], to quantify membrane transporters in fresh lung from five donors, in four immortalized human lung cell lines and in three control cell lines. We quantify twelve
-
In conclusion we have shown that mGlu
2023-06-02

In conclusion, we have shown that mGlu7 receptors negatively regulate α1-adrenergic receptor signalling in heterologous expression systems, Embelin tissue and living animals. This interaction might represent a protective mechanism aimed at restraining an excessive activation of noradrenergic transm
-
In conclusion we have shown that mGlu
2023-06-02

In conclusion, we have shown that mGlu7 receptors negatively regulate α1-adrenergic receptor signalling in heterologous expression systems, Embelin tissue and living animals. This interaction might represent a protective mechanism aimed at restraining an excessive activation of noradrenergic transm
-
In conclusion we have shown that mGlu
2023-06-02

In conclusion, we have shown that mGlu7 receptors negatively regulate α1-adrenergic receptor signalling in heterologous expression systems, Embelin tissue and living animals. This interaction might represent a protective mechanism aimed at restraining an excessive activation of noradrenergic transm
-
br Introduction In myasthenia gravis MG autoantibodies again
2023-05-31

Introduction In myasthenia gravis (MG), autoantibodies against the native AChR conformation cause loss of AChR at the neuromuscular junction and fatigable muscle weakness (Newsom-Davis et al., 1993). The AChR is a pentameric transmembrane protein, with two splice forms of the α-subunit, P3A− and
-
br Introduction In myasthenia gravis MG autoantibodies again
2023-05-31

Introduction In myasthenia gravis (MG), autoantibodies against the native AChR conformation cause loss of AChR at the neuromuscular junction and fatigable muscle weakness (Newsom-Davis et al., 1993). The AChR is a pentameric transmembrane protein, with two splice forms of the α-subunit, P3A− and
-
It involves complementary and inflammatory system proteins m
2023-05-30

It involves complementary and inflammatory system proteins, mast cells, eosinophils, basophils, macrophages, natural killer (NK) cells and cytokines [1]. Innate immunity, not only include cells, but also barriers that defend the organism to the penetration of pathogenic agents [2]. Important mediat
-
Evidences have suggested that impairment of
2023-05-30

Evidences have suggested that impairment of CK activity contributes to inhibition of Na+, K+-ATPase and H+-ATPase activities during infectious diseases, since these ATPases are dependent of ATP, as observed by Baldissera et al. [31] in fish experimentally infected by Aeromonas caviae. We observed th
-
In this review we will present the traditional and actual
2023-05-30

In this review, we will present the traditional and actual strategies to study orphan receptors and identify their ligands. An extensive description of the orphan GPCR field has been published in 2013 by Davenport et al. [22]. Therefore, we will focus on the deorphanizations that were reported since
-
Patients with cardiovascular disorders typically have
2023-05-29

Patients with cardiovascular disorders typically have lower plasma apelin levels than matched healthy controls. For example, plasma apelin levels are reduced in patients with coronary artery disease (CAD), and among CAD patients with unstable angina or acute myocardial infraction there is a further
-
It has been proposed that a
2023-05-29

It has been proposed that a PrP pathogenic mechanism is a toxic gain of function secondary to the misfolding of mutated PrP. However, such a mechanism might not apply to all mutant PrP species, since some mutations had little effect on the stability and folding kinetics of PrP (Swietnicki et al., 19
-
br Epidemiology br Genetics The dominantly inherited
2023-05-29

Epidemiology Genetics The dominantly inherited PrP cerebral amyloidoses are genetically transmitted with a penetrance of almost 100%. Early linkage analysis studies helped to established the relationship between GSS and mutations in the PRNP gene. PRNP is located on the short arm of chromosome
15199 records 307/1014 page Previous Next First page 上5页 306307308309310 下5页 Last page